These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26873634)

  • 1. Prednisolone- and sirolimus-eluting stent: Anti-inflammatory approach for inhibiting in-stent restenosis.
    Lee SY; Bae IH; Sung Park D; Jang EJ; Shim JW; Lim KS; Park JK; Sim DS; Jeong MH
    J Biomater Appl; 2016 Jul; 31(1):36-44. PubMed ID: 26873634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a novel peptide, WKYMVm- and sirolimus-coated stent on re-endothelialization and anti-restenosis.
    Jang EJ; Bae IH; Park DS; Lee SY; Lim KS; Park JK; Shim JW; Sim DS; Jeong MH
    J Mater Sci Mater Med; 2015 Oct; 26(10):251. PubMed ID: 26438653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local perivascular delivery of anti-restenotic agents from a drug-eluting poly(epsilon-caprolactone) stent cuff.
    Pires NM; van der Hoeven BL; de Vries MR; Havekes LM; van Vlijmen BJ; Hennink WE; Quax PH; Jukema JW
    Biomaterials; 2005 Sep; 26(26):5386-94. PubMed ID: 15814137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of in-stent restenosis with sirolimus-eluting-stents -- a six month clinical and angiographic follow-up.
    Rau M; Maikowski C; Weber M; Keil E; Elsässer A; Möllmann H; Hamm C
    Z Kardiol; 2005 Nov; 94(11):742-7. PubMed ID: 16258776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary restenotic reduction of drug-eluting stenting may be due to its anti-inflammatory effects.
    Li JJ; Li J; Nan JL; Li Z; Zhen X; Mu CW; Dai J; Zhang CY
    Med Hypotheses; 2007; 69(5):1004-9. PubMed ID: 17499449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a sirolimus-eluting poly (L-lactide)/poly(4-hydroxybutyrate) absorbable stent for peripheral vascular intervention.
    Grabow N; Bünger CM; Kischkel S; Timmermann JH; Reske T; Martin DP; Williams SF; Schareck W; Sternberg K; Schmitz KP
    Biomed Tech (Berl); 2013 Oct; 58(5):429-37. PubMed ID: 23898020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.
    Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Bruining N; Van den Branden F; Van Langenhove G
    J Am Coll Cardiol; 2006 Dec; 48(12):2423-31. PubMed ID: 17174178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus coating on heparinized stents prevents restenosis and thrombosis.
    Bae IH; Lim KS; Park DS; Shim JW; Lee SY; Jang EJ; Park JK; Kim JH; Jeong MH
    J Biomater Appl; 2017 May; 31(10):1337-1345. PubMed ID: 28436251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis.
    Kollum M; Farb A; Schreiber R; Terfera K; Arab A; Geist A; Haberstroh J; Wnendt S; Virmani R; Hehrlein C
    Catheter Cardiovasc Interv; 2005 Jan; 64(1):85-90. PubMed ID: 15619311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of dextran-based sirolimus-eluting stents and PLA-based sirolimus-eluting stents in vitro and in vivo.
    Lee SY; Bae IH; Park DS; Jang EJ; Shim JW; Lim KS; Park JK; Sim DS; Jeong MH
    J Biomed Mater Res A; 2017 Jan; 105(1):301-310. PubMed ID: 27615559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmable elution profile coating for drug eluting stents.
    Al-Lamee K
    Med Device Technol; 2005 Mar; 16(2):12-5. PubMed ID: 15828493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fabrication and characteristics of dual functionalized vascular stent by spatio-temporal coating.
    Kim SM; Park KS; Lih E; Hong YJ; Kang JH; Kim IH; Jeong MH; Joung YK; Han DK
    Acta Biomater; 2016 Jul; 38():143-52. PubMed ID: 27109766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravascular ultrasound comparison of sirolimus-eluting stent versus bare metal stent implantation in diseased saphenous vein grafts (from the RRISC [Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent] trial).
    Agostoni P; Vermeersch P; Semeraro O; Verheye S; Van Langenhove G; Van den Heuvel P; Convens C; Van den Branden F; Bruining N
    Am J Cardiol; 2007 Jul; 100(1):52-8. PubMed ID: 17599440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angioscopic findings after drug-eluting stent implantation.
    Takano M; Mizuno K
    Herz; 2007 Jun; 32(4):281-6. PubMed ID: 17607534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of sirolimus-eluting stent implantation for recurrent in-stent restenosis after brachytherapy.
    Saia F; Lemos PA; Sianos G; Degertekin M; Lee CH; Arampatzis CA; Hoye A; Tanabe K; Regar E; van der Giessen WJ; Smits PC; de Feyter P; Ligthart J; van Domburg RT; Serruys PW
    Am J Cardiol; 2003 Jul; 92(2):200-3. PubMed ID: 12860224
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibition of experimental neointimal hyperplasia and neoatherosclerosis by local, stent-mediated delivery of everolimus.
    Zhao HQ; Nikanorov A; Virmani R; Schwartz LB
    J Vasc Surg; 2012 Dec; 56(6):1680-8. PubMed ID: 22841285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus-eluting stents in the canine cerebral vasculature: a prospective, randomized, blinded assessment of safety and vessel response.
    Levy EI; Hanel RA; Howington JU; Nemes B; Boulos AS; Tio FO; Paciorek AM; Amlani S; Kagan-Hallett KS; Fronckowiak MD; Guterman LR; Hopkins LN
    J Neurosurg; 2004 Apr; 100(4):688-94. PubMed ID: 15070124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surface-mediated transfection of a pDNA vector encoding short hairpin RNA to downregulate TGF-β1 expression for the prevention of in-stent restenosis.
    Zhang H; Ren KF; Chang H; Wang JL; Ji J
    Biomaterials; 2017 Feb; 116():95-105. PubMed ID: 27914270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Stents coated with sirolimus and anti-CD34 antibody can optimize the performance of sirolimus-eluting stents].
    Song XT; Zhu HG; Yang XS; Yuan F; Lü SZ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Nov; 39(11):997-1004. PubMed ID: 22336451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.